Listed below is a summary of 2022, 2023, and 2024 highlights for IDSA guidelines as well as guidelines endorsed by IDSA.
|
Guideline |
Publication Date |
Journal |
|---|---|---|
| Guidelines Released in 2024 |
||
| IDSA Guidelines | ||
| Lab ID Guidance (Joint with ASM) | 3/2024 | Clinical Infectious Diseases |
|
Updates to COVID-19 guidelines: |
2/2024 |
IDSA and Clinical Infectious Diseases |
| Guidelines Released in 2023 |
||
| IDSA Guidelines | ||
| Bone and Joint Infections: Acute Bacterial Arthritis in Pediatrics | 11/2023 | IDSA and Pediatric Infectious Diseases Society |
| New Fever in Critically Ill Patients | 11/2023 | IDSA and Society of Critical Care Medicine |
| Diabetic Foot Infections | 10/2023 | Clinical Infectious Diseases and Diabetes/Metabolism Research and Reviews |
| Antimicrobial Resistance Update | 6/2023 | IDSA and Clinical Infectious Diseases |
| Compendia on Catheter-Associated Urinary Tract Infections | 6/2023 | Infection Control & Hospital Epidemiology |
| 5/2023 | IDSA and Clinical Infectious Diseases | |
|
SHEA/IDSA/APIC Compendia Update for: |
Ongoing | Infection Control & Hospital Epidemiology |
| Updates to COVID-19 guidelines: Treatment and Management Diagnostics: Antigen Testing Diagnostics: Molecular |
Ongoing | IDSA and Clinical Infectious Diseases |
| Guidelines Released in 2022 |
||
| IDSA Guidelines | ||
| Updated Guidance on Antimicrobial-Resistant Gram-Negative Infections, v1.1: ESBL-E, CRE, and Pseudomonas aeruginosa with Difficult-to-Treat Resistance | 3/2022 | IDSA and Clinical Infectious Diseases |
| Updates to COVID-19 guidelines: Treatment and Management |
Ongoing |
IDSA and Clinical Infectious Diseases |
|
SHEA/IDSA/APIC Compendia for:
|
Ongoing
|
Infection Control & Hospital Epidemiology |
| Endorsed Guidelines | ||
| ACEP Sepsis Report | 7/2021 | Annals of Emergency Medicine |
| Surviving Sepsis Campaign: Management of Sepsis and Septic Shock | 11/2021 | Critical Care Medicine |
Listed below is a summary of IDSA guidelines in development and topics prioritized for future development.
|
Guideline |
Publication Date (Estimated) |
Journal |
|---|---|---|
| Guidelines in Development |
||
| Updates to COVID-19 guidelines: Treatment and Management Infection Prevention Diagnostics: Molecular Testing Diagnostics: Antigen Testing |
Ongoing | IDSA and Clinical Infectious Diseases |
| Intra-Abdominal Infections (Multi-Part Series) | 2024, Q2 (Part 1) | Clinical Infectious Diseases |
| Treatment of Uncomplicated Urinary Tract Infections (Multi-Part Series) | 2024, Q3 (Part 1) | Clinical Infectious Diseases |
| Community-Acquired Pneumonia in Adults (Joint with ATS) | 2024, Q2 | American Journal of Respiratory and Critical Care Medicine |
| Drug-Susceptible and Drug-Resistant Tuberculosis (Joint with ATS/ERS/CDC) | 2024, Q2 | American Journal of Respiratory and Critical Care Medicine |
| Community-Acquired Pneumonia in Children (Joint with PIDS) | 2024, Q3 | Clinical Infectious Diseases |
| Antimicrobial Prophylaxis in Surgery (Joint with ASHP/SHEA/SIS) | 2024, Q4 | American Journal of Health-System Pharmacy |
| Immunomodulators | 2024, Q4 | Clinical Infectious Diseases |
| Strep Pharyngitis (Multi-Part Series) | 2024, Q3 (Part 1) | Clinical Infectious Diseases |
| Histoplasmosis (Multi-Part Series) | 2024, Q4 (Part 1) | Clinical Infectious Diseases |
| Staphylococcus aureus Bacteremia (Joint with ESCMID) (Multi-Part Series) | 2024, Q4 | Clinical Infectious Diseases |
| IV Catheter | 2024, Q4 | Clinical Infectious Diseases |
| Aspergillosis (Multi-Part Series) | 2024, Q4 (Part 1) | Clinical Infectious Diseases |
| HBV (Joint with AASLD) | 2024, Q4 | Hepatology |
| Guidelines Prioritized for Development |
||
| Management of Cryptococcosis | TBD | TBD |
| Management of HAP/VAP | TBD | TBD |
| Diagnosis and Management of Prosthetic Joint Infections | TBD | TBD |
| Diagnosis and Management of Skin and Soft Tissue Infections | TBD | TBD |
| Management of Enterococcal Infections (including Vancomycin-Resistant Enterococcus) (NEW TOPIC) | TBD | TBD |